High Concentrations of Aspartame Induce Pro-Angiogenic Effects in Ovo and Cytotoxic Effects in HT-29 Human Colorectal Carcinoma Cells.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
24 Nov 2020
Historique:
received: 31 10 2020
revised: 20 11 2020
accepted: 22 11 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 23 4 2021
Statut: epublish

Résumé

Aspartame (ASP), an artificial sweetener abundantly consumed in recent years in an array of dietary products, has raised some concerns in terms of toxicity, and it was even suggested a link with the risk of carcinogenesis (colorectal cancer), though the present scientific data are rather inconclusive. This study aims at investigating the potential role of aspartame in colorectal cancer by suggesting two experimental approaches: (i) an in vitro cytotoxicity screening in HT-29 human colorectal carcinoma cells based on cell viability (Alamar blue assay), cell morphology and cell migration (scratch assay) assessment and (ii) an in ovo evaluation in terms of angiogenic and irritant potential by means of the chorioallantoic membrane method (CAM). The in vitro results showed a dose-dependent cytotoxic effect, with a significant decrease of viable cells at the highest concentrations tested (15, 30 and 50 mM) and morphological cellular changes. In ovo, aspartame (15 and 30 mM) proved to have a pro-angiogenic effect and a weak irritant potential at the vascular level. These data suggest new directions of research regarding aspartame's role in colorectal cancer.

Identifiants

pubmed: 33255204
pii: nu12123600
doi: 10.3390/nu12123600
pmc: PMC7760274
pii:
doi:

Substances chimiques

Angiogenesis Inducing Agents 0
Cytotoxins 0
Sweetening Agents 0
Aspartame Z0H242BBR1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : The National Council for Financing Higher Education
ID : CNFIS-FDI-2019-0393

Références

J Invest Dermatol. 2017 Feb;137(2):e11-e16
pubmed: 28110712
Reprod Toxicol. 2017 Jun;70:97-101
pubmed: 27832950
Regul Toxicol Pharmacol. 2019 Apr;103:332-344
pubmed: 29339245
Am J Ind Med. 2014 Apr;57(4):383-97
pubmed: 24436139
Yale J Biol Med. 2010 Jun;83(2):101-8
pubmed: 20589192
Food Chem Toxicol. 1985 Feb;23(2):287-91
pubmed: 4040077
PLoS One. 2014 Oct 14;9(10):e109841
pubmed: 25313461
Arch Public Health. 2019 Jul 15;77:34
pubmed: 31338189
PLoS One. 2018 Jul 19;13(7):e0199244
pubmed: 30024889
Oncol Rep. 2020 Sep;44(3):1169-1183
pubmed: 32705265
Hum Exp Toxicol. 2015 Mar;34(3):260-5
pubmed: 24925367
Adv Nutr. 2019 Jan 1;10(suppl_1):S31-S48
pubmed: 30721958
Crit Rev Toxicol. 2007;37(8):629-727
pubmed: 17828671
Food Chem Toxicol. 2011 Jun;49(6):1203-7
pubmed: 21376768
Drug Chem Toxicol. 2015;38(3):318-27
pubmed: 25317478
Molecules. 2018 Sep 25;23(10):
pubmed: 30257473
Molecules. 2014 Apr 17;19(4):4924-40
pubmed: 24747649
Cent Eur J Public Health. 2014 Dec;22(4):215-22
pubmed: 25622477
Protein Cell. 2018 May;9(5):474-487
pubmed: 29713943
Nutr Rev. 2017 Sep 1;75(9):718-730
pubmed: 28938797
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32486066
Nutr Rev. 2016 Nov;74(11):670-689
pubmed: 27753624
Turk J Med Sci. 2020 Mar 28;50(2):448-454
pubmed: 32222132
Food Chem Toxicol. 2019 Feb;124:385-399
pubmed: 30557670
Int J Mol Sci. 2018 Nov 28;19(12):
pubmed: 30487390
Nutrients. 2019 Jan 14;11(1):
pubmed: 30646512
Nutrients. 2020 Apr 21;12(4):
pubmed: 32326137
Environ Toxicol Pharmacol. 2014 Jan;37(1):158-65
pubmed: 24355796
Toxicol Sci. 2000 Jan;53(1):33-9
pubmed: 10653518
Int J Biol Macromol. 2015 May;76:236-41
pubmed: 25748846
Int J Toxicol. 2016 Nov;35(6):627-633
pubmed: 27733445
Br J Sports Med. 2018 Jul;52(14):910-913
pubmed: 28835408
Toxicol In Vitro. 2011 Feb;25(1):286-93
pubmed: 20837131
Saudi J Biol Sci. 2016 Jul;23(4):503-6
pubmed: 27298583
Toxicol Res (Camb). 2015 Sep 29;5(1):45-52
pubmed: 30090325
Front Pharmacol. 2017 Mar 14;8:109
pubmed: 28352231
Ann Anat. 2019 Jul;224:133-141
pubmed: 31108189
Nutrients. 2019 May 02;11(5):
pubmed: 31052523
J Pharmacol Pharmacother. 2011 Oct;2(4):236-43
pubmed: 22025850
Toxicol In Vitro. 2020 Feb;62:104694
pubmed: 31655124
Mol Aspects Med. 2019 Oct;69:93-106
pubmed: 31082399
Regul Toxicol Pharmacol. 2019 Apr;103:352-362
pubmed: 30716379
Oncol Res Treat. 2018;41(4):188-193
pubmed: 29562227

Auteurs

Anca Laura Maghiari (AL)

Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Dorina Coricovac (D)

Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Iulia Andreea Pinzaru (IA)

Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Ioana Gabriela Macașoi (IG)

Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Iasmina Marcovici (I)

Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Sebastian Simu (S)

Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Dan Navolan (D)

Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Cristina Dehelean (C)

Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, RO-300041 Timișoara, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH